Complete Remission of Plasmablastic Lymphoma With Daratumumab and a Mild Regimen of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (Mini-CHOP).

Plasmablastic lymphoma (PBL) is a rare and highly aggressive subtype of diffuse large B-cell lymphoma, characterized by a dismal prognosis. Due to its rarity and aggressive nature, no established standard of care exists for PBL. Treatment is primarily based on large B-cell lymphoma- or multiple myeloma-based chemotherapy regimens, and outcomes remain poor. We present an 84-year-old man with an extensive oncologic history who presented with PBL on his right foot which did not respond to subsequent radiation treatment. A mild regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (mini-CHOP) normally utilized to treat large B-cell lymphoma was supplemented with the CD38-directed monoclonal antibody, daratumumab. This combination regimen was selected for the elderly patient due to his weakened condition. Upon six cycles of daratumumab-mini-CHOP, the patient achieved complete remission.